Received: 11 May 2022
Accepted: 12 September 2022
First Online: 18 October 2022
: This study is not considered research involving human subjects in accordance with the United States Department of Health and Human Services regulation 45 CFR part 46 Subpart A and thus review by an institutional review board was not required.
: Not applicable; no patient data were collected.
: Dorothee Oberdhan is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.Myrlene Sanon Aigbogun was an employee of Otsuka at the time of the study.Stephen Seliger has received research funding from Otsuka, Kadmon Pharmaceuticals, Sanofi, Palladio Biosciences, and Reata Pharmaceuticals.Christine Barnett, Gregory Mader, Deirdre Mladsi, and Molly Purser were employees of RTI Health Solutions at the time of this study, which received funding under a research contract with Otsuka to conduct this study. Their compensation is unconnected to the studies on which they work.Terry Watnick has nothing to disclose.